Rivaroxaban data at the ACC Annual Scientific Session

April 2 - 5, 2011
New Orleans, USA

Findings from the Phase III MAGELLAN study of Rivaroxaban were presented during at the Annual Scientific Session of the American College of Cardiology (ACC) in New Orleans, USA, on April 5, 2011, 3:00 p.m. - 3:12 p.m. CEST. On this occasion we held a conference call for investors and analysts.

Tuesday, April 5, 2011 at approx. 4:00 p.m. CEST (2:00 p.m. GMT):
Investor Conference Call on Rivaroxaban

Dr. Kemal Malik, Head of Global Development at Bayer HealthCare Pharmaceuticals 
Dr. Frank Misselwitz, Head Therapeutic Area Cardiovascular and Coagulation, Global Clinical Development
Dr. Alexander Rosar, Head of Investor Relations

MP3 audio recording (presentation and discussion)